Ann: Litigation Update, page-49

Not suggesting this is what is covered in "documents filed", but this apparently is what was proposed: LINK


'PFM says the proposed claim will allege that Mesoblast engaged in misleading or deceptive conduct and breached its continuous disclosure obligations throughout the claim period (22 February 2018 and 17 December 2020) by:

"Misrepresenting the efficacy and potential benefit of treating patients with R-L;
Misrepresenting the significance of trial results, including the relevance of earlier studies, post hoc analysis and data collated for controls and contrast;
Not disclosing to the market material information, including the deficiencies in study design and statistics presented;
Not disclosing all information required for investors to be able to reasonably assess the likelihood of whether R-L would be shown to be effective in treating SR-aGHVD or COVID-19 ARDS, and then be commercialised on that basis
“As a result of the above conduct, Mesoblast’s security price was artificially inflated and that investors suffered loss and damage by the acquisition of Mesoblast shares and ADRs at inflated prices,” PFM said.'


Anyway, for the class action that was never going to happen the next stop is:

29-Jul-2022 9:30 First Case Management Hearing Justice Beach

Just sayin'.

TC MDN's & DYOR